EA201790929A1 - Плазмидная днк, кодирующая hnp-1, либо hnp-2, либо hnp-3, бактериальный продуцент, анальгетическое средство (варианты) - Google Patents
Плазмидная днк, кодирующая hnp-1, либо hnp-2, либо hnp-3, бактериальный продуцент, анальгетическое средство (варианты)Info
- Publication number
- EA201790929A1 EA201790929A1 EA201790929A EA201790929A EA201790929A1 EA 201790929 A1 EA201790929 A1 EA 201790929A1 EA 201790929 A EA201790929 A EA 201790929A EA 201790929 A EA201790929 A EA 201790929A EA 201790929 A1 EA201790929 A1 EA 201790929A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hnp
- variants
- plasmid dna
- analgesia
- analgetic
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title abstract 3
- 101000830386 Homo sapiens Neutrophil defensin 3 Proteins 0.000 title abstract 2
- 101800000287 Neutrophil defensin 2 Proteins 0.000 title abstract 2
- 230000000202 analgesic effect Effects 0.000 title abstract 2
- 230000001580 bacterial effect Effects 0.000 title abstract 2
- 102000018475 human neutrophil peptide 2 Human genes 0.000 title abstract 2
- GRZXCHIIZXMEPJ-HTLKCAKFSA-N neutrophil peptide-2 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@@H](N)CSSC[C@H](NC2=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 GRZXCHIIZXMEPJ-HTLKCAKFSA-N 0.000 title abstract 2
- 101000918983 Homo sapiens Neutrophil defensin 1 Proteins 0.000 title 1
- 102100029494 Neutrophil defensin 1 Human genes 0.000 title 1
- 102100024761 Neutrophil defensin 3 Human genes 0.000 title 1
- KRJOFJHOZZPBKI-KSWODRSDSA-N α-defensin-1 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H](CSSC[C@H](NC2=O)C(O)=O)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 KRJOFJHOZZPBKI-KSWODRSDSA-N 0.000 title 1
- 230000036592 analgesia Effects 0.000 abstract 3
- 239000000730 antalgic agent Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000018568 alpha-Defensin Human genes 0.000 abstract 1
- 108050007802 alpha-defensin Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 102000018476 human neutrophil peptide 3 Human genes 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000010474 transient expression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение (варианты) относится к области медицины, фармакологии, биотехнологии, молекулярной биологии, генной инженерии и может быть использовано для анальгезии. Предложена плазмидная ДНК для транзиентной экспрессии в клетках млекопитающих, представленная остовом, содержащим прокариотические и эукариотические элементы, и полинуклеотидом, кодирующим альфа дефенсин человека HNP-1, либо HNP-2, либо HNP-3 (варианты). Также предложен продуцент такой плазмидной ДНК на основе бактериальной клетки (варианты) и анальгетическое средство для применения у млекопитающих, в частности человека, на его основе (варианты). Технический результат от использования вариантов изобретения выражается в расширении спектра анальгетических средств, в увеличении длительности анальгезии, в увеличении безопасности анальгезии, в упрощении и удешевлении производства анальгетика.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014145169/15A RU2597789C2 (ru) | 2014-11-10 | 2014-11-10 | Анальгетическое средство на основе плазмидной днк, кодирующей hnp-1, либо hnp-2, либо hnp-3 (варианты) |
PCT/RU2015/000756 WO2016076761A1 (ru) | 2014-11-10 | 2015-11-10 | Плазмидная днк, кодирующая hnp-1, либо hnp-2, либо hnp-3, бактериальный продуцент, анальгетическое средство (варианты) |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201790929A1 true EA201790929A1 (ru) | 2017-09-29 |
EA038673B1 EA038673B1 (ru) | 2021-10-01 |
Family
ID=55954714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790929A EA038673B1 (ru) | 2014-11-10 | 2015-11-10 | Плазмидная днк, кодирующая дефенсин hnp-1, либо hnp-2, либо hnp-3 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20180057837A1 (ru) |
EP (1) | EP3219798B1 (ru) |
JP (1) | JP2017535288A (ru) |
KR (1) | KR20170077252A (ru) |
CN (1) | CN107208087A (ru) |
BR (1) | BR112017009607A2 (ru) |
EA (1) | EA038673B1 (ru) |
HK (1) | HK1243732A1 (ru) |
IL (1) | IL252730B (ru) |
RU (1) | RU2597789C2 (ru) |
WO (1) | WO2016076761A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA036780B1 (ru) * | 2017-11-26 | 2020-12-21 | Илья Владимирович ДУХОВЛИНОВ | Плазмидная днк, кодирующая бета-эндорфин, бактериальный продуцент, анальгетическое средство |
US11358895B2 (en) * | 2018-11-15 | 2022-06-14 | Owens-Brockway Glass Container Inc. | Batch charger for a melting chamber |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2767832B1 (fr) * | 1997-08-29 | 2001-08-10 | Genset Sa | Polypeptide defensine humaine def-x, adn genomique et adnc, composition les contenant et applications au diagnostic et au traitement therapeutique |
JP2002238568A (ja) * | 2001-02-14 | 2002-08-27 | Jenokkusu Soyaku Kenkyusho:Kk | アレルギー性疾患の検査方法 |
WO2003070176A2 (en) * | 2002-02-19 | 2003-08-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Modified defensins and their use |
EP2769990A3 (en) * | 2004-12-02 | 2015-02-25 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY |
EP1863836B1 (en) * | 2005-03-18 | 2012-07-11 | Novozymes Adenium Biotech A/S | Polypeptides having antimicrobial activity and polynucleotides encoding same |
CN101175770A (zh) * | 2005-03-18 | 2008-05-07 | 诺维信公司 | 具有抗微生物活性的多肽和编码该多肽的多核苷酸 |
CN100445371C (zh) * | 2005-10-18 | 2008-12-24 | 甘肃亚盛盐化工业集团有限责任公司 | 一种利用大肠杆菌生产人α防御素1蛋白的方法 |
CN1904036B (zh) * | 2005-10-18 | 2010-09-01 | 甘肃亚盛盐化工业集团有限责任公司 | 基因工程菌混合培养生产三种人α防御素的方法 |
FR2893619A1 (fr) * | 2005-11-21 | 2007-05-25 | Chu Nice | Proteine chimere lectine-defensine |
JP2010539065A (ja) * | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのペプチドの使用 |
CN101280318B (zh) * | 2008-05-30 | 2011-05-11 | 四川大学 | 重组人hnp基因脂质体复合物、制备方法及用途 |
CN101648011B (zh) * | 2008-08-11 | 2012-06-13 | 同济大学附属上海市肺科医院 | 一种肿瘤靶向重组dna疫苗及其制备与应用 |
CN102586256A (zh) * | 2012-01-16 | 2012-07-18 | 华南理工大学 | 人β-防御素3在酵母菌表达系统中的表达方法 |
EP2833923A4 (en) * | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS |
RU2012114261A (ru) * | 2012-04-10 | 2013-10-20 | Илья Владимирович Духовлинов | Анальгетическое средство на основе плазмидной днк |
-
2014
- 2014-11-10 RU RU2014145169/15A patent/RU2597789C2/ru active
-
2015
- 2015-11-10 JP JP2017544270A patent/JP2017535288A/ja active Pending
- 2015-11-10 KR KR1020177015883A patent/KR20170077252A/ko unknown
- 2015-11-10 EA EA201790929A patent/EA038673B1/ru unknown
- 2015-11-10 BR BR112017009607-2A patent/BR112017009607A2/pt not_active Application Discontinuation
- 2015-11-10 WO PCT/RU2015/000756 patent/WO2016076761A1/ru active Application Filing
- 2015-11-10 US US15/524,782 patent/US20180057837A1/en not_active Abandoned
- 2015-11-10 EP EP15858310.4A patent/EP3219798B1/en not_active Not-in-force
- 2015-11-10 CN CN201580072724.XA patent/CN107208087A/zh active Pending
-
2017
- 2017-06-06 IL IL25273017A patent/IL252730B/en active IP Right Grant
-
2018
- 2018-03-07 HK HK18103246.6A patent/HK1243732A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017535288A (ja) | 2017-11-30 |
CN107208087A (zh) | 2017-09-26 |
EP3219798B1 (en) | 2019-07-17 |
EA038673B1 (ru) | 2021-10-01 |
EP3219798A1 (en) | 2017-09-20 |
BR112017009607A2 (pt) | 2018-04-03 |
WO2016076761A1 (ru) | 2016-05-19 |
RU2014145169A (ru) | 2016-05-27 |
EP3219798A4 (en) | 2018-04-25 |
RU2597789C2 (ru) | 2016-09-20 |
KR20170077252A (ko) | 2017-07-05 |
IL252730A0 (en) | 2017-08-31 |
US20180057837A1 (en) | 2018-03-01 |
IL252730B (en) | 2019-10-31 |
HK1243732A1 (zh) | 2018-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
PH12019500706A1 (en) | Cyclic dinucleotide compounds | |
PH12020551744A1 (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
WO2015155686A3 (en) | Methods and compositions for rna-directed repression of transcription using crispr-associated genes | |
AU2015286820A8 (en) | Stabilization of poly(A) sequence encoding DNA sequences | |
AR068552A1 (es) | Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas | |
EP4303314A3 (en) | Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection | |
EA201790698A1 (ru) | Новые сайты интеграции cho и их применения | |
MX2020012240A (es) | Agentes de ligacion agonistas del receptor tnf. | |
CA3062698A1 (en) | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof | |
MX2016015743A (es) | Compuestos de ciclopropilamina como inhibidores de histona demetilasa. | |
BR112016027897A2 (pt) | polipeptídio multimérico, ácido nucleico, vetor de expressão recombinante, célula hospedeira geneticamente modificada, composição, método, e, método de tratamento de uma infecção num indivíduo | |
EP4241784A3 (en) | Artificial nucleic acid molecules for improved protein expression | |
BR112016014462A2 (pt) | moléculas de ácido nucleico artificiais | |
EP3381438A4 (en) | COMPOSITION FOR THE INJECTION OF HYALURONIC ACID CONTAINING A HYALURONIC ACID DERIVATIVE AND A DNA FRACTION, AND THE USE THEREOF | |
MX2011007467A (es) | Dominios modulares de union a dna y metodos de uso. | |
MX2021008318A (es) | Nuevos polipeptidos de union especifica y usos de los mismos. | |
MX2014009975A (es) | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. | |
BR112017012482A2 (pt) | copolímero estático, composição, uso de um copolímero, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção do copolímero. | |
BR112018069823A2 (pt) | molécula de dna, vetor, célula hospedeira, composição, molécula de rna, molécula de ácido nucleico, composição farmacêutica, kit, e, uso de uma utr | |
MX2020005458A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
PH12020552291A1 (en) | System and methods for engineering bacteria fit for eukaryotic mrna production, export, and translation in a eukaryotic host | |
EA201790929A1 (ru) | Плазмидная днк, кодирующая hnp-1, либо hnp-2, либо hnp-3, бактериальный продуцент, анальгетическое средство (варианты) | |
MX2021004688A (es) | Distrofinas miniaturizadas y usos de las mismas. |